Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone ResistancePatrick N. A. Harris, David L. Paterson, Souha S. Kanj et al.|JAMA|2018Cited by 761
Initial antimicrobial management of sepsisMichael S. Niederman, Girish B. Nair, Rebecca M. Baron et al.|Critical Care|2021Cited by 176
Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO StudyAndrew Henderson, Bassam Alalwan, David L. Paterson et al.|Clinical Infectious Diseases|2020Cited by 155
The<i>Staphylococcus aureus</i>Network Adaptive Platform Trial Protocol: New Tools for an Old FoeSteven Y. C. Tong, Adrian Dunlop, Jocelyn Mora et al.|Clinical Infectious Diseases|2022Cited by 98
Frailty and Potentially Inappropriate Medication Use at Nursing Home TransitionLaura C. Maclagan, Susan E. Bronskill, Sima Gandhi et al.|Journal of the American Geriatrics Society|2017Cited by 86